Sierra Oncology is a pharmaceutical company that is dedicated to developing and bringing to market the drug momelotinib. This drug is designed to inhibit JAK1, JAK2 & ACVR1, which could potentially cure myelofibrosis. This condition weakens patients by causing anemia, constitutional symptoms, and enlarges the spleen. Since their clinical studies began over a decade ago, over 1,200 patients have received momelotinib, and it has been shown to be effective in treating the symptoms of myelofibrosis. The company is focused on successfully registering and launching momelotinib for medical use.